With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The WAVEsystem with the WAVEcontrol 4.0 embedded
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
